SciBase expands US reach, advancing early melanoma detection with AI-powered technology

TAGS

Holding AB (STO: SCIB), a leader in AI-driven solutions, has taken a significant step forward in its US expansion strategy by onboarding multiple dermatology practices specializing in diagnosis. This expansion aims to make SciBase’s innovative Nevisense technology more accessible to clinicians across the country, enhancing their ability to conduct early detection and improve patient outcomes.

The company’s growing presence in the United States reflects a broader push to equip dermatologists with advanced dermatology technology advancements, allowing for more precise and timely skin cancer assessments.

How Is SciBase Revolutionizing Early Melanoma Detection?

Melanoma is the deadliest form of skin cancer, with the American Cancer Society estimating that nearly 8,000 people die from the disease annually in the US. However, when detected at an early stage, melanoma is highly treatable, with survival rates exceeding 99%. Despite this, diagnosing early-stage melanoma remains a challenge, as traditional visual assessments and dermoscopy rely on subjective interpretation.

SciBase’s Nevisense system transforms skin cancer diagnosis by integrating AI-powered dermatology technology advancements with Electrical Impedance Spectroscopy (EIS), offering a non-invasive method to analyze cellular changes beneath the skin’s surface. This breakthrough allows clinicians to make more informed biopsy decisions, reducing unnecessary procedures while ensuring that high-risk cases receive immediate attention.

See also  SkinBioTherapeutics partners with Umesh Modi Group for Dermatonics launch in AMEA

“The early melanoma detection capability of Nevisense provides a crucial advantage in clinical practice,” said Dr. Michael McPhee, surgical oncologist and managing director of the Melanoma Clinic in Orlando, Florida. “With approximately 20 people dying from melanoma each day in the US, we must improve diagnostic accuracy at the point of care. Nevisense allows us to detect cancer at its earliest and most treatable stage, potentially saving lives.”

Why Is AI Transforming Skin Cancer Diagnosis?

Traditional methods of assessing atypical moles involve dermoscopic evaluation and, in cases of uncertainty, surgical biopsy. However, these approaches can be limited by the clinician’s experience and the subtle nature of early-stage melanoma. SciBase’s Nevisense introduces an evidence-based, AI-powered approach to skin cancer diagnosis, offering a level of diagnostic precision that surpasses conventional techniques.

Dr. Alison Z. Young, a dermatologist and dermatopathologist at Young Dermatology in Seattle, Washington, highlighted the challenges of evaluating suspicious lesions.

See also  Lilly to acquire US dermatology drug company Dermira for $1.1bn

“Many early melanomas exhibit very few visible morphological features, making them difficult to assess with the naked eye,” Dr. Young explained. “Nevisense provides cellular data from below the skin’s surface, allowing us to improve patient care by identifying high-risk lesions before making a biopsy decision. This represents a major dermatology technology advancement in precision diagnostics.”

What Sets SciBase Apart in the Dermatology Market?

SciBase has been at the forefront of dermatological innovation for over two decades, developing solutions that blend AI with early melanoma detection technologies. The company’s Nevisense system is designed to support dermatologists in their efforts to reduce unnecessary biopsies, lower healthcare costs, and enhance patient safety.

“Our mission is to equip healthcare professionals with cutting-edge skin cancer diagnosis tools that improve diagnostic accuracy and enable proactive disease management,” said Pia Renaudin, CEO of SciBase. “Expanding our presence in the US market allows us to work closely with clinicians who share our commitment to advancing skin cancer care.”

With its foundation in research conducted at Sweden’s Karolinska Institute, SciBase has established itself as a global leader in dermatology-focused AI-powered technology advancements. Since 2015, the company has been publicly traded on Nasdaq First North Growth Market, with Carnegie Investment Bank AB (publ) serving as its Certified Adviser.

See also  Medtronic secures $337m from Blackstone to develop diabetes technologies

How Will SciBase’s Expansion Impact the Future of Dermatology?

By onboarding new US dermatology practices, SciBase is positioning itself as a key player in the evolving landscape of early melanoma detection. The company’s focus on expanding access to Nevisense aligns with a broader industry shift toward AI-driven diagnostic tools that improve accuracy and efficiency in skin cancer diagnosis.

As more dermatologists adopt Nevisense, the potential for dermatology technology advancements to reshape patient care continues to grow. With melanoma cases rising globally, innovative solutions like Nevisense will play a crucial role in ensuring early intervention and better clinical outcomes.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This